Joseph Thome
Stock Analyst at TD Cowen
(4.74)
# 691
Out of 5,081 analysts
433
Total ratings
47.1%
Success rate
15.7%
Average return
Main Sectors:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Reiterated: Buy | $10 | $3.00 | +233.33% | 23 | Oct 21, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $140 → $145 | $83.27 | +74.13% | 12 | Oct 21, 2026 | |
| TLV: TEVA Teva Pharmaceutical Industries Limited | Initiated Coverage: Buy | ILA 17,081 | ILA 12,250 | +39.43% | 1 | Oct 1, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | n/a | $3.61 | - | 11 | Sep 24, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | n/a | $25.33 | - | 17 | Sep 22, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | n/a | $35.77 | - | 18 | Sep 18, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | n/a | $11.26 | - | 22 | Sep 4, 2026 | |
| QURE uniQure | Reiterated: Buy | n/a | $21.65 | - | 28 | Sep 2, 2026 | |
| UTHR United Therapeutics | Reiterated: Buy | $675 | $592.84 | +13.86% | 32 | Sep 2, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $300 | $205.70 | +45.84% | 31 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $58.98 | - | 9 | Aug 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $61.07 | +47.37% | 48 | Aug 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $48.77 | - | 25 | Aug 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $27.09 | - | 8 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $51.09 | - | 9 | Aug 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.42 | - | 2 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.7674 | - | 13 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $300 → $315 | $144.06 | +118.66% | 35 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $18.66 | - | 5 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $23.34 | - | 17 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $58 | $44.44 | +30.51% | 21 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.72 | - | 2 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.66 | - | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.75 | - | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.98 | - | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.50 | n/a | 9 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 5 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $40 | $194.25 | n/a | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $10.20 | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $126.23 | n/a | 1 | Oct 1, 2020 |
Ardelyx
Oct 21, 2026
Reiterated: Buy
Price Target: $10
Current: $3.00
Upside: +233.33%
Mirum Pharmaceuticals
Oct 21, 2026
Reiterated: Buy
Price Target: $140 → $145
Current: $83.27
Upside: +74.13%
Teva Pharmaceutical Industries Limited
Oct 1, 2026
Initiated Coverage: Buy
Price Target: ILA 17,081
Current: ILA 12,250
Upside: +39.43%
Prime Medicine
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.61
Upside: -
Rapport Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.33
Upside: -
Xenon Pharmaceuticals
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $35.77
Upside: -
Intellia Therapeutics
Sep 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.26
Upside: -
uniQure
Sep 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.65
Upside: -
United Therapeutics
Sep 2, 2026
Reiterated: Buy
Price Target: $675
Current: $592.84
Upside: +13.86%
Jazz Pharmaceuticals
Aug 31, 2026
Reiterated: Buy
Price Target: $300
Current: $205.70
Upside: +45.84%
Aug 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $58.98
Upside: -
Aug 30, 2026
Reiterated: Buy
Price Target: $90
Current: $61.07
Upside: +47.37%
Aug 25, 2026
Rated: Buy
Price Target: n/a
Current: $48.77
Upside: -
Aug 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $27.09
Upside: -
Aug 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $51.09
Upside: -
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.42
Upside: -
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.7674
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: $300 → $315
Current: $144.06
Upside: +118.66%
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $18.66
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $23.34
Upside: -
Jul 28, 2026
Reiterated: Buy
Price Target: $57 → $58
Current: $44.44
Upside: +30.51%
Jul 28, 2026
Reiterated: Buy
Price Target: n/a
Current: $15.72
Upside: -
May 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.66
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.75
Upside: -
Nov 5, 2025
Reiterated: Buy
Price Target: n/a
Current: $1.98
Upside: -
Jul 19, 2024
Rated: Hold
Price Target: n/a
Current: $14.50
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
May 24, 2023
Reiterated: Hold
Price Target: $40
Current: $194.25
Upside: n/a
Oct 10, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $10.20
Upside: n/a
Oct 1, 2020
Reiterated: Buy
Price Target: n/a
Current: $126.23
Upside: n/a